These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 7891710)

  • 21. Definition of a consensus binding site for p53.
    el-Deiry WS; Kern SE; Pietenpol JA; Kinzler KW; Vogelstein B
    Nat Genet; 1992 Apr; 1(1):45-9. PubMed ID: 1301998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Roles of p53 Family Structure and Function in Non-Canonical Response Element Binding and Activation.
    Cai BH; Chao CF; Huang HC; Lee HY; Kannagi R; Chen JY
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation.
    Anderson ME; Woelker B; Reed M; Wang P; Tegtmeyer P
    Mol Cell Biol; 1997 Nov; 17(11):6255-64. PubMed ID: 9343386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A PAb240+ conformation of wild type p53 binds DNA.
    McLure KG; Lee PW
    Oncogene; 1996 Sep; 13(6):1297-303. PubMed ID: 8808704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region.
    Selivanova G; Iotsova V; Kiseleva E; Ström M; Bakalkin G; Grafström RC; Wiman KG
    Nucleic Acids Res; 1996 Sep; 24(18):3560-7. PubMed ID: 8836183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High affinity insertion/deletion lesion binding by p53. Evidence for a role of the p53 central domain.
    Szak ST; Pietenpol JA
    J Biol Chem; 1999 Feb; 274(6):3904-9. PubMed ID: 9920946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity.
    Bayle JH; Elenbaas B; Levine AJ
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5729-33. PubMed ID: 7777576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequence-dependent cooperative binding of p53 to DNA targets and its relationship to the structural properties of the DNA targets.
    Beno I; Rosenthal K; Levitine M; Shaulov L; Haran TE
    Nucleic Acids Res; 2011 Mar; 39(5):1919-32. PubMed ID: 21071400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors.
    Dreyfus DH; Nagasawa M; Gelfand EW; Ghoda LY
    BMC Immunol; 2005 Jun; 6():12. PubMed ID: 15969767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53.
    Dornan D; Shimizu H; Burch L; Smith AJ; Hupp TR
    Mol Cell Biol; 2003 Dec; 23(23):8846-61. PubMed ID: 14612423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA.
    Balagurumoorthy P; Sakamoto H; Lewis MS; Zambrano N; Clore GM; Gronenborn AM; Appella E; Harrington RE
    Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8591-5. PubMed ID: 7567980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domain.
    Göhler T; Reimann M; Cherny D; Walter K; Warnecke G; Kim E; Deppert W
    J Biol Chem; 2002 Oct; 277(43):41192-203. PubMed ID: 12171916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor suppressor protein p53 binds preferentially to supercoiled DNA.
    Palecek E; Vlk D; Stanková V; Brázda V; Vojtesek B; Hupp TR; Schaper A; Jovin TM
    Oncogene; 1997 Oct; 15(18):2201-9. PubMed ID: 9393978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Redox state regulates binding of p53 to sequence-specific DNA, but not to non-specific or mismatched DNA.
    Parks D; Bolinger R; Mann K
    Nucleic Acids Res; 1997 Mar; 25(6):1289-95. PubMed ID: 9092641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches.
    Lee S; Elenbaas B; Levine A; Griffith J
    Cell; 1995 Jun; 81(7):1013-20. PubMed ID: 7600570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A DNA binding domain is contained in the C-terminus of wild type p53 protein.
    Foord OS; Bhattacharya P; Reich Z; Rotter V
    Nucleic Acids Res; 1991 Oct; 19(19):5191-8. PubMed ID: 1923804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of mutant p53 temperature-sensitive DNA binding.
    Friedlander P; Legros Y; Soussi T; Prives C
    J Biol Chem; 1996 Oct; 271(41):25468-78. PubMed ID: 8810317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recognition of DNA modified by antitumor cisplatin by "latent" and "active" protein p53.
    Fojta M; Pivonkova H; Brazdova M; Kovarova L; Palecek E; Pospisilova S; Vojtesek B; Kasparkova J; Brabec V
    Biochem Pharmacol; 2003 Apr; 65(8):1305-16. PubMed ID: 12694871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
    Kaku S; Iwahashi Y; Kuraishi A; Albor A; Yamagishi T; Nakaike S; Kulesz-Martin M
    Nucleic Acids Res; 2001 May; 29(9):1989-93. PubMed ID: 11328884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different recognition of DNA modified by aatitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53.
    Kasparkova J; Pospisilova S; Brabec V
    J Biol Chem; 2001 May; 276(19):16064-9. PubMed ID: 11279186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.